prikaz prve stranice dokumenta SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
  Preuzmi
PDF 1.26 MB
Znanstveni rad - Izvorni znanstveni rad
SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
Plos pathogen, 17 (2021), 12; e1010175. https://doi.org/10.1371/journal.ppat.1010175
Chaouat, Abigael Eva; Achdout, Hagit; Kol, Inbal; Berhani, Orit; Roi, Gil; Vitner, Einat B.; Melamed, Sharon; Politi, Boaz; Zahavy, Eran; Brizić, Ilija; Lenac Roviš, Tihana; Alfi, Or; Wolf, Dana; Jonjić, Stipan; Israely, Tomer; Mandelboim, Ofer Više autora...

Povezani objekti
COVID-19 (zbirka 2.) | Virtualna zbirka

Institucijski repozitorij: Repozitorij Medicinskog fakulteta u Rijeci

Citirajte ovaj rad

Chaouat, A. E., Achdout, H., Kol, I., Berhani, O., Roi, G., Vitner, E. B. ... Mandelboim, O. (2021). SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection. Plos pathogen, 17. (12). doi: 10.1371/journal.ppat.1010175

Chaouat, Abigael Eva, et al. "SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection." Plos pathogen, vol. 17, br. 12, 2021. https://doi.org/10.1371/journal.ppat.1010175

Chaouat, Abigael Eva, Hagit Achdout, Inbal Kol, Orit Berhani, Gil Roi, Einat B. Vitner, Sharon Melamed, et al. "SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection." Plos pathogen 17, br. 12 (2021). https://doi.org/10.1371/journal.ppat.1010175

Chaouat, A. E., et al. (2021) 'SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection', Plos pathogen, 17(12). doi: 10.1371/journal.ppat.1010175

Chaouat AE, Achdout H, Kol I, Berhani O, Roi G, Vitner EB, i sur.. SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection. Plos pathogen [Internet]. 20.12.2021. [pristupljeno 23.11.2024.];17(12). doi: 10.1371/journal.ppat.1010175

A. E. Chaouat, et al., "SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection", Plos pathogen, vol. 17, br. 12, Prosinac 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:864171. [Citirano: 23.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:864171
Podaci o radu
Naslov (engleski)SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection
AutorAbigael Eva Chaouat
AutorHagit Achdout
AutorInbal Kol
AutorOrit Berhani
AutorGil Roi
AutorEinat B. Vitner
AutorSharon Melamed
AutorBoaz Politi
AutorEran Zahavy
AutorIlija Brizić
AutorTihana Lenac Roviš
AutorOr Alfi
AutorDana Wolf
AutorStipan Jonjić
AutorTomer Israely
AutorOfer Mandelboim
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Centar za proteomiku)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Sažetak (engleski)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic. Currently, as dangerous mutations emerge, there is an increased demand for specific treatments for SARS-CoV-2 infected patients. The spike glycoprotein on the virus envelope binds to the angiotensin converting enzyme 2 (ACE2) on host cells through its receptor binding domain (RBD) to mediate virus entry. Thus, blocking this interaction may inhibit viral entry and consequently stop infection. Here, we generated fusion proteins composed of the extracellular portions of ACE2 and RBD fused to the Fc portion of human IgG1 (ACE2-Ig and RBD-Ig, respectively). We demonstrate that ACE2-Ig is enzymatically active and that it can be recognized by the SARS-CoV-2 RBD, independently of its enzymatic activity. We further show that RBD-Ig efficiently inhibits in-vivo SARS-CoV-2 infection better than ACE2-Ig. Mechanistically, we show that anti-spike antibody generation, ACE2 enzymatic activity, and ACE2 surface expression were not affected by RBD-Ig. Finally, we show that RBD-Ig is more efficient than ACE2-Ig at neutralizing high virus titers. We thus propose that RBD-Ig physically blocks virus infection by binding to ACE2 and that RBD-Ig should be used for the treatment of SARS-CoV-2-infected patients.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPlos pathogen
Brojčani podacivol. 17, br. 12, e1010175
p-ISSN1553-7374
e-ISSN1553-7374
DOIhttps://doi.org/10.1371/journal.ppat.1010175
URN:NBNurn:nbn:hr:184:864171
Datum objave publikacije2021-12-20
ProjektŠifra: IP-CORONA-2020-04-2073
Naziv (hrvatski): Dosta skrivanja CoV-2: uspostava baze monoklonskih protutijela na SARS-Cov-2
Naziv (engleski): No more hiding CoV-2: Establishment of SARS-Cov-2 mAbeom
Kratica: CoV2mAbs
Voditelj: Ilija Brizić
Pravna nadležnost: Hrvatska
Financijer: HRZZ
Linija financiranja: IP-CORONA
ProjektŠifra: KK.011.1.01.0006
Naziv (hrvatski): Jačanje kapaciteta CerVirVac-a za istraživanja u virusnoj imunologiji i vakcinologiji
Voditelj: Stipan Jonjić
Pravna nadležnost: eu
Financijer: ERDF
ProjektŠifra: N/A
Naziv (hrvatski): Centar izvrsnosti za virusnu imunologiju i cjepiva
Naziv (engleski): Centre of Excellence for Research in Viral Immunology and the Development of New Vaccines
Kratica: CERVirVac
Voditelj: Stipan Jonjić
Pravna nadležnost: Hrvatska
Financijer: MZOS
Linija financiranja: ZCI
URL dokumentahttps://dx.plos.org/10.1371/journal.ppat.1010175
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-04-06 11:24:16